12:00 AM
 | 
Feb 23, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Conbriza bazedoxifene regulatory update

EMEA's CHMP issued a positive opinion on an MAA from Wyeth for Conbriza bazedoxifene to treat postmenopausal osteoporosis at increased risk...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >